A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

On August 9, Fundstrat’s Tom Lee appeared on CNBC to discuss the current state of the market and the potential for further ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...